Back to News
Market Impact: 0.2
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
Source: businesswire.com
Company FundamentalsTechnology & InnovationHealthcare & BiotechProduct Launches
NeoGenomics said it has expanded MolDX coverage for its RaDaR ST MRD assay, used for immunotherapy monitoring in late-stage solid tumors. The update is incremental and supportive for commercialization, but no financial figures or guidance changes were provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
NEO0.30
More News
- Bending Spoons wants to revive software castoffs. Berkshire is backing the plan
- Microsoft, Shopify and 3 more AI stocks that are favorite Wall Street earnings plays
- Why did CoreWeave stock get crushed this week? Look to this corner of the debt market for clues
- Christine Lagarde: IMFC Statement
- Palantir patient data tech rejected by many NHS trusts in England
- AI stock sell-off ramps up over debt-fueled data center spending fears: ‘Full-blown crisis of confidence'